Bridging the gap between innovation and capital
Nextech Invest
Focus on Therapeutic Biotech Companies
Program
Nextech is a global therapeutics-focused venture capital firm headquartered in Zurich, Switzerland with affiliate offices in Boston and San Francisco. They invest in companies developing promising therapeutics for oncology and oncology-adjacent disease areas. They invest in all stages, from Series A to publicly listed investments, and in companies at different phases, from discovery to clinical development. They are active investors and closely engage with portfolio companies, with the goal of helping to shape some of the best new biotechnology companies.
Event
LaunchBio and Silicon Valley Bank, a division of First Citizens Bank, are pleased to announce their next Investor Connect virtual event with Nextech
Applications will be selected based on meeting the following criteria:
Geography:
Global, but mostly US and Europe
Company type:
Therapeutics with a focus on oncology and oncology-adjacent indications, stage and modality-agnostic
Areas of Interest:
- Biologics
- Cell therapies
- Protein-based therapies
- RNA-based therapeutics
- Small molecule
Research areas of interest include, but are not limited to:
- Oncology and Oncology-adjacent areas (primary)
- Immunology
- Cardiology
- Dermatology
Stage:
Companies seeking funding for Series A, Series B and beyond.
Qualifying start-ups can apply here today.
Applications are accepted on a rolling basis. Learn more about LaunchBio’s Investor Connect series, in partnership with Silicon Valley Bank, a division of First Citizens Bank.